Skip to main content
. 2021 Jun 3;10(1):1016–1023. doi: 10.1080/22221751.2021.1931465

Figure 1.

Figure 1.

Identification of immune linear epitopes of SARS-CoV-2 ORF8 protein using the serum of COVID-19 patients. (A) Localization and sequences of the peptides on SARS-CoV-2 ORF8 protein (NCBI Reference Sequence: YP_009724396.1) as shown. (B) Sera of COVID-19 patients (n = 40) at 3–64 days post-symptom onse at 1:100 dilution were subjected to peptide-based ELISA using paptide covering the entire ORF8 protein in (A). The landscape of adjusted epitope-specific antibody levels in each COVID-19 patient (n = 40) is shown. The ELISA results as patient OD values subtracted of cut-off values are presented, negative values are plotted as zero. The cut-off for seropositivity was set as the mean value of individual control serum sample or serum pools of serum taken in October 2019 (n = 100) plus two times of standard deviation. (C) The seropositive rates of each peptide in COVID-19 patients (n = 40) in (B) were determined. (D) Associations of anti-ORF8 peptide 1, 2, 8 and 15 and anti-ORF8 recombinant protein IgG in the sera of COVID-19 patients at 13–64 days’ post-symptom onset (n = 33). p Values were calculated by Pearson correlation coefficients. Data were presented as mean ± standard deviation. Not Significant, n.s. p > .05.